Evidence map›Paper›PMID 23639648›Full record

ReviewGastroenterology clinics of North America2013

Gastrointestinal stromal tumors.

Markku Miettinen, Jerzy Lasota

Abstract readReview
In one paragraph

Review in Gastroenterology clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Markku MiettinenLaboratory of Pathology, NCI/NIH, Bethesda, MD 20892, USA. miettinenmm@mail.nih.gov
Jerzy Lasota

Funding

Genreal Surgical PathologyZIDBC011291 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MIETTINEN, MARKKU · 2010 to 2025
$30.3M
Immunohistochemical and genomic analysis of tumorsZIABC011427 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MIETTINEN, MARKKU · 2012 to 2025
$24.0M
Intramural NIH HHS ZID BC011291
6 · The paper itself

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal tract. Soon after GIST was recognized as a tumor driven by a KIT or platelet-derived growth factor receptor mutation, it became the first solid tumor target for tyrosine kinase inhibitor therapies. More recently, alternative molecular mechanisms for GIST pathogenesis have been discovered. These are related to deficiencies in the succinate dehydrogenase complex, NF1-gene alterations in connection with neurofibromatosis type 1 tumor syndrome, and mutational activation of the BRAF oncogene in very rare cases.

Indexed as

Abdominal PainGastrointestinal HemorrhageGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHumansNeurofibromatosis 1Platelet-Derived Growth FactorPrognosisProto-Oncogene Proteins c-kitSuccinate DehydrogenasePlatelet-Derived Growth Factorplatelet-derived growth factor AProto-Oncogene Proteins c-kitSuccinate Dehydrogenase

Identifiers

PMID23639648
PMCPMC3644178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.